Pfizer sees lung cancer drug topping $1 billion in sales following impressive 5-year data

Pfizer (PFE.N) said it expects its cancer drug Lorbrena to top $1 billion in annual sales by 2030 on the strength of data presented on Friday showing most patients treated for a rare form of advanced lung cancer in a clinical trial were alive without the disease worsening after five years.